Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF

    European Journal of Heart Failure Date published:

  • Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas

    European Journal of Heart Failure Date published:

  • Is Placebo Still Ethical in Trials of Incretin Therapies?

    Circulation Date published:

  • Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials

    European Heart Journal Date published:

  • Kidney Disease and Heart Failure: Recent Advances and Current Challenges

    JACC: Heart Failure Date published:

  • Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

    JACC: Heart Failure Date published:

  • Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International Date published:

  • SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to <20ml/min/1.73m2

    Journal of Cardiac Failure Date published:

  • The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis

    Clinical Journal of the American Society of Nephrology Date published:

  • Cardiac Impact of Dapagliflozin in Advanced Chronic Kidney Disease: Rationale and Design of the Renal Lifecycle Trial Cardiac Imaging Sub-studies

    Clinical Kidney Journal Date published:

  • UTILIZING RISK PREDICTION MODELS FOR OLDER PATIENTS WITH CHRONIC KIDNEY DISEASE

    Kidney International Date published:

  • Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials

    Diabetes Care Date published:

  • Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria

    JAMA Date published:

  • SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria

    JAMA Date published:

  • A meta-analysis of albuminuria as a surrogate endpoint for kidney failure

    Nature Medicine Date published:

  • Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes

    JACC Date published: